This site is intended for healthcare professionals
Industry news

Alliqua merges with Adynxx to create a new company to promote brivoligide for the reduction of long term pain relief and the reduction of opioids.

Read time: 1 mins
Last updated:15th Oct 2018
Published:15th Oct 2018
Source: Pharmawand
Alliqua BioMedical, Inc. and Adynxx, Inc., a privately held biopharmaceutical company, announced that they have entered into a definitive merger agreement under which the stockholders of Adynxx would become the majority owners of Alliqua�s outstanding common stock on a fully-diluted basis. The proposed merger will create a public clinical-stage pharmaceutical company focused on developing a platform of first-in-class, disease-modifying, non-opioid therapies for the treatment of pain. Adynxx�s lead product candidate, brivoligide for the reduction of postoperative pain, is intended to provide long-term pain relief and reduced opioid usage with a single administration at the time of surgery in a group of patients with a greater risk of experiencing increased and prolonged pain following surgery.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.